BMS Just Paid to Solve Its Patent Cliff With Someone Else’s Pipeline
Bristol Myers Squibb's 13-program deal with Hengrui Pharma is the clearest signal yet that Western pharma's next growth decade...
No videos found.
Chinese Biotechs Shift From Building to Partnering as Deal Values Double
At BIO China, pharma executives and investors debated whether Chinese biotechs should pursue full integration or adopt partnership-led growth...
The Vein That Learns to Belong: VERIGRAFT’s Biological Bet on Curing Chronic Venous Insufficiency
Petter Björquist CEO, VERIGRAFT Chronic venous insufficiency affects an estimated 150 million people worldwide, yet the clinical toolkit has...
Oragenics Licenses CardioDialysis Technology for TBI Treatment
Oragenics licenses CardioDialysis technology for TBI treatment in exclusive deal involving 3.25M shares of preferred stock convertible to common.
Genmab Q1 2026 Royalties Jump 26% to $742 Million
Genmab Q1 2026 royalties jump 26% to $742 million, driven by daratumumab and ofatumumab sales from Johnson & Johnson...
Zymeworks Reports Q1 2026 Results, Awaits August FDA Decision on Zanidatamab
Zymeworks awaits August FDA decision on zanidatamab for HER2-positive gastroesophageal adenocarcinoma, with $250M milestone payment at stake.
BridgeBio Posts $180.6M Attruby Revenue, Authorizes $500M Buyback
BridgeBio posts $180.6M Attruby revenue in Q1 2026, authorizing $500M buyback as the rare disease drug drives commercial expansion.
Crinetics’ Palsonify Reaches 70% Reimbursement Rate in Q1 2026 Launch
Crinetics' Palsonify achieves 70% reimbursement rate in Q1 2026 launch, nearly doubling sequential revenue with 232 new patient enrollments.
MoonLake’s Sonelokimab Clears FDA Pre-BLA Meeting for Hidradenitis Suppurativa
MoonLake's sonelokimab for hidradenitis suppurativa achieved a 29-percentage-point placebo-adjusted response rate, positioning it above current competitors in F
Innovent’s Triple Breakthrough Play: IBI363 Just Became the Most Dangerous Asset in Immuno-Oncology’s Coldest Corner
Innovent's IBI363 scores its third NMPA Breakthrough Therapy Designation—this time for MSS/pMMR colorectal cancer, the tumor type that killed...